Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. The company is headquartered in Silver Spring, Maryland and currently employs 51 full-time employees. The company went IPO on 2020-10-08. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Follow-Up Questions
Who is the CEO of Elutia Inc?
Dr. C. Randal Mills is the President of Elutia Inc, joining the firm since 2015.
What is the price performance of ELUT stock?
The current price of ELUT is $1.08, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Elutia Inc?
Elutia Inc belongs to Biotechnology industry and the sector is Health Care
What is Elutia Inc market cap?
Elutia Inc's current market cap is $45.7M
Is Elutia Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Elutia Inc, including 2 strong buy, 5 buy, 1 hold, 0 sell, and 2 strong sell
